Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors
Key Points
This disposition involved 3,500 shares at $38.42 per share, totaling $134,470.
The transaction reduced the director's total equity holdings by 20%, based on holdings reported in the Form 4.
The shares were held directly; no indirect holdings or entities were reported in this transaction.
- 10 stocks we like better than AtriCure ›
Maggie Yuen, a director at AtriCure, Inc. (NASDAQ:ATRC), reported a sale of 3,500 shares of common stock on August 5, 2026, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $134,470 |
| Shares sold | 3,500 |
| Post-transaction shares (directly held) | 14,015 |
| Post-transaction value | $551,350.10 |
Transaction value based on SEC Form 4 weighted average sale price ($38.42); post-transaction value based on August 05, 2026 market close ($39.34).
Key questions
- What was the scale of the transaction relative to the insider's total position?
Yuen reduced her direct equity stake by 20%, bringing her total beneficial ownership to 14,015 shares. - How does the execution price compare to recent market levels?
The 3,500 shares were sold at a weighted average price of $38.42, which was slightly below the $39.34 market close on the day of the transaction. Shares have shown relative stability, priced at $39.49 as of the August 6 market close. - What is the company's current financial profile in the healthcare sector?
AtriCure is a medical device company with a market capitalization of $2.0 billion. The firm reported trailing twelve-month revenue of $569.6 million, maintaining a focus on specialized cardiac treatment technologies.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-06) | $39.49 |
| Market Capitalization | $2.0 billion |
| Revenue (TTM) | $569.6 million |
Company Snapshot
- AtriCure designs, manufactures, and markets specialized medical devices for the surgical treatment of cardiac tissue and intercostal nerves, including radiofrequency ablation technologies such as the Isolator Synergy Clamps and multifunctional surgical pens like the MAX Pen that enable surgeons to diagnose and treat cardiac arrhythmias.
- The company generates revenue through the sale of proprietary ablation and surgical devices to hospitals and surgical centers, leveraging its specialized technology platform to address unmet clinical needs in cardiac surgery and arrhythmia management.
- AtriCure serves cardiac surgeons and surgical teams across the United States, Europe, Asia, and other international markets, with its products integrated into standard surgical protocols for atrial fibrillation and other cardiac conditions.
AtriCure is a focused medical device company with a $2.0 billion market capitalization and $569.6 million in TTM revenue, positioning itself as a specialized provider of cardiac surgical solutions. The company maintains a differentiated product portfolio centered on radiofrequency ablation technology, which provides competitive advantages in the treatment of cardiac arrhythmias and related conditions. With a global distribution network spanning multiple continent, AtriCure has established itself as a significant player in the cardiac surgery device market.
What this transaction means for investors
Two AtriCure directors sold on the same day, and Yuen's cut ran deeper in percentage terms, clearing a fifth of her direct stake in one go. That kind of matching timing might mean a trading window opened after earnings and a couple of board members stepped through it together, not that either soured on the company.
More importantly for long-term investors, the company gave them a solid quarter to sell into. AtriCure grew second-quarter revenue 13% to $154 million, and its appendage-management franchise, built around its AtriClip devices for reducing stroke risk, rose 14% on newer Mini versions. CEO Michael Carrel pointed to growth "fueled by continued adoption" across its franchises, and gross margin widened to 77%, all of which helped management lift its full-year outlook. Shares have recovered quite a bit since June lows of around $25, surging more than 60%, and they’re up about 15% over the past year. After a strong quarter, whether the latest momentum continues will depend a lot on continued execution — much more than share sales like this one.
Should you buy stock in AtriCure right now?
Before you buy stock in AtriCure, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AtriCure wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $397,405!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,344,091!*
Now, it’s worth noting Stock Advisor’s total average return is 953% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 7, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
